Alzprotect: Alzprotect : Forges Ahead with First Patients Enrolled in Phase 2a Study in Progressive Supranuclear Palsy (PSP)

(marketscreener.com) ALZPROTECT , a biopharmaceutical company developing treatments for Alzheimer's disease, today announced the recruitment of the first 5 patients to participate in its phase 2a clinical trial with its drug candidate AZP2006 in Progressive Supranuclear Palsy , an orphan disease for which the company has been granted with the "orphan...https://www.marketscreener.com/news/latest/Alzprotect-Forges-Ahead-with-First-Patients-Enrolled-in-Phase-2a-Study-in-Progressive-Supranuclear--31287684/?utm_medium=RSS&utm_content=20200914